{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360004231520002048.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1007/s12185-013-1404-y"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1007/s12185-013-1404-y.pdf"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/article/10.1007/s12185-013-1404-y/fulltext.html"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1007/s12185-013-1404-y"}},{"identifier":{"@type":"PMID","@value":"23934275"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial"}],"description":[{"notation":[{"@value":"Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, progressive hematopoietic stem cell disorder characterized by chronic complement-mediated hemolysis leading to life-threatening complications and early mortality. Eculizumab, a humanized anti-C5 monoclonal antibody, inhibits terminal complement activation, reduces hemolysis, decreases the risk of thrombosis, and improves renal function and quality of life in PNH patients. The long-term efficacy and safety of eculizumab in Japanese patients were assessed in a 2-year extension to a 12-week, open-label study (AEGIS). Eculizumab treatment led to an immediate and sustained reduction in intravascular hemolysis (P0.001) and red blood cell transfusions (P = 0.0016) compared with baseline levels. There were no reports of thromboembolism during eculizumab treatment. The majority of patients had stable (56 %) or improved (41 %) renal function and an improved quality of life (P = 0.015), with sustained reductions in fatigue and dyspnea. Eculizumab was well tolerated; no deaths or serious hemolytic events were reported, and the rate of infections declined over time. There were no significant differences in the response to eculizumab in patients with or without bone marrow dysfunction. These results demonstrate that eculizumab is an effective, well-tolerated long-term treatment for Japanese PNH patients and leads to continued amelioration of some hemolytic complications."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380004231520002057","@type":"Researcher","foaf:name":[{"@value":"Yuzuru Kanakura"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231520001926","@type":"Researcher","foaf:name":[{"@value":"Kazuma Ohyashiki"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231520001934","@type":"Researcher","foaf:name":[{"@value":"Tsutomu Shichishima"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231520001935","@type":"Researcher","foaf:name":[{"@value":"Shinichiro Okamoto"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231520002061","@type":"Researcher","foaf:name":[{"@value":"Kiyoshi Ando"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231520001931","@type":"Researcher","foaf:name":[{"@value":"Haruhiko Ninomiya"}]},{"@id":"https://cir.nii.ac.jp/crid/1420001326221362560","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"50244116"},{"@type":"NRID","@value":"1000050244116"},{"@type":"NRID","@value":"9000259831582"},{"@type":"NRID","@value":"9000000480591"},{"@type":"NRID","@value":"9000022060221"},{"@type":"NRID","@value":"9000256570712"},{"@type":"NRID","@value":"9000258044767"},{"@type":"NRID","@value":"9000021106639"},{"@type":"NRID","@value":"9000256570823"},{"@type":"NRID","@value":"9000020063850"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/7000016841"}],"foaf:name":[{"@value":"Tatsuya Kawaguchi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231520002177","@type":"Researcher","foaf:name":[{"@value":"Shinji Nakao"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231520002066","@type":"Researcher","foaf:name":[{"@value":"Hideki Nakakuma"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231520001932","@type":"Researcher","foaf:name":[{"@value":"Jun-ichi Nishimura"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231520002180","@type":"Researcher","foaf:name":[{"@value":"Taroh Kinoshita"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231520002055","@type":"Researcher","foaf:name":[{"@value":"Camille L. Bedrosian"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231520002070","@type":"Researcher","foaf:name":[{"@value":"Keiya Ozawa"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231520002062","@type":"Researcher","foaf:name":[{"@value":"Mitsuhiro Omine"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"09255710"},{"@type":"EISSN","@value":"18653774"}],"prism:publicationName":[{"@value":"International Journal of Hematology"}],"dc:publisher":[{"@value":"Springer Science and Business Media LLC"}],"prism:publicationDate":"2013-08-11","prism:volume":"98","prism:number":"4","prism:startingPage":"406","prism:endingPage":"416"},"reviewed":"false","dc:rights":["http://www.springer.com/tdm"],"url":[{"@id":"http://link.springer.com/content/pdf/10.1007/s12185-013-1404-y.pdf"},{"@id":"http://link.springer.com/article/10.1007/s12185-013-1404-y/fulltext.html"},{"@id":"http://link.springer.com/content/pdf/10.1007/s12185-013-1404-y"}],"createdAt":"2013-08-10","modifiedAt":"2022-03-03","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Adult","dc:title":"Adult"},{"@id":"https://cir.nii.ac.jp/all?q=Male","dc:title":"Male"},{"@id":"https://cir.nii.ac.jp/all?q=Hemoglobinuria,%20Paroxysmal","dc:title":"Hemoglobinuria, Paroxysmal"},{"@id":"https://cir.nii.ac.jp/all?q=Complement%20C5","dc:title":"Complement C5"},{"@id":"https://cir.nii.ac.jp/all?q=Middle%20Aged","dc:title":"Middle Aged"},{"@id":"https://cir.nii.ac.jp/all?q=Antibodies,%20Monoclonal,%20Humanized","dc:title":"Antibodies, Monoclonal, Humanized"},{"@id":"https://cir.nii.ac.jp/all?q=Treatment%20Outcome","dc:title":"Treatment Outcome"},{"@id":"https://cir.nii.ac.jp/all?q=Japan","dc:title":"Japan"},{"@id":"https://cir.nii.ac.jp/all?q=Risk%20Factors","dc:title":"Risk Factors"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Immunologic%20Factors","dc:title":"Immunologic Factors"},{"@id":"https://cir.nii.ac.jp/all?q=Female","dc:title":"Female"},{"@id":"https://cir.nii.ac.jp/all?q=Aged","dc:title":"Aged"}],"project":[{"@id":"https://cir.nii.ac.jp/crid/1040000782245914880","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"25293220"},{"@type":"JGN","@value":"JP25293220"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-25293220/"}],"notation":[{"@language":"ja","@value":"抗アポトーシス分子アナモルシンの機能解析　-造血と細胞内鉄代謝における役割-"},{"@language":"en","@value":"Analysis of the functions of anti-apoptotic molecule, Anamorsin -the roles in hematopoiesis and cellular iron metabolism-"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360011144019072768","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145101651840","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145211138560","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Under‐recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283690462826496","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS Clinical Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285711328015232","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Improvement of Renal Function by Long-Term Sustained Eculizumab Treatment in a Patient with Paroxysmal Nocturnal Hemoglobinuria"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292618575761792","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The pathophysiology of paroxysmal nocturnal hemoglobinuria"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292619320428672","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620343107584","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Association Between Elevated Hemolysis at Diagnosis and Early Mortality and Risk of Thrombosis In Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients with Cytopenia"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620498265088","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620868255872","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"D-Dimers, Thrombin—Antithrombin Complexes, and Risk Factors for Thromboembolism in Hospitalized Patient"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620946352640","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Cerebral Ischemic Infarction in Paroxysmal Nocturnal Hemoglobinuria"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292621439569280","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298343138996224","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prevalence of paroxysmal nocturnal hemoglobinuria (PNH) cells in patients with myelodysplastic syndromes (MDS), aplastic anemia (AA), or other bone marrow failure (BMF) syndromes: Interim results from the EXPLORE trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360576118763460096","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848656450657920","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848656451201792","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855568917447168","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Aplastic anemia and paroxysmal nocturnal hemoglobinuria: search for a pathogenetic link"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865814739182336","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Interim analysis of post-marketing surveillance of ravulizumab for paroxysmal nocturnal hemoglobinuria in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1360869855581060736","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prevention and Management of Thromboembolism in Patients with Paroxysmal Nocturnal Hemoglobinuria in Asia: A Narrative Review"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137043472549504","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137044446697344","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045131497344","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Paroxysmal nocturnal hemoglobinuria following alemtuzumab immunosuppressive therapy for myelodysplastic syndrome and complicated by recurrent life-threatening thrombosis despite anticoagulation: Successful intervention with eculizumab and fondaparinux"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519257517824","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hemolysis and Acute Kidney Failure"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519485022976","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519642951424","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH)"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995239652992","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995825442176","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469005259008","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A population-based study of the incidence and outcomes of diagnosed chronic kidney disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469848782336","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effect of eculizumab on haemolysis‐associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470825314048","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The spectrum of PIG-A gene mutations in aplastic anemia/paroxysmal nocturnal hemoglobinuria (AA/PNH): a high incidence of multiple mutations and evidence of a mutational hot spot"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981471263683712","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944487737216","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944504468480","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544418884052608","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419426274688","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419651032448","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419822655360","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544421214936448","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825894983093120","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene."}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895445926400","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388843632047488","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The Aplastic Anaemia–Paroxysmal Nocturnal Haemoglobinuria Syndrome"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844768855936","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Natural History of Paroxysmal Nocturnal Hemoglobinuria"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670319443650688","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320731082368","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Fatigue in cancer patients compared with fatigue in the general United States population"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670321276014080","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical Course and Flow Cytometric Analysis of Paroxysmal Nocturnal Hemoglobinuria in the United States and Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795113106304","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233268694767488","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Eculizumab"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233268735436544","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Somatic mutations of the PIG-A gene found in Japanese patients with paroxysmal nocturnal hemoglobinuria"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269642080896","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Diagnosis and management of paroxysmal nocturnal hemoglobinuria"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270168155264","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Heme protein-induced chronic renal inflammation: Suppressive effect of induced heme oxygenase-1"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270913528704","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1007/s12185-013-1404-y"},{"@type":"KAKEN","@value":"PRODUCT-15001912"},{"@type":"OPENAIRE","@value":"doi_dedup___::096b1057d84ba5367333454c062a6d56"},{"@type":"CROSSREF","@value":"10.1155/2015/673195_references_DOI_UtsX5K2wk8ZtvSEniJtWQc9j23i"},{"@type":"CROSSREF","@value":"10.1007/s12185-022-03287-y_references_DOI_UtsX5K2wk8ZtvSEniJtWQc9j23i"},{"@type":"CROSSREF","@value":"10.1007/s12185-016-1946-x_references_DOI_UtsX5K2wk8ZtvSEniJtWQc9j23i"},{"@type":"CROSSREF","@value":"10.1007/s12185-018-2409-3_references_DOI_UtsX5K2wk8ZtvSEniJtWQc9j23i"},{"@type":"CROSSREF","@value":"10.1007/s12185-023-03625-8_references_DOI_UtsX5K2wk8ZtvSEniJtWQc9j23i"},{"@type":"CROSSREF","@value":"10.3390/ijms26062504_references_DOI_UtsX5K2wk8ZtvSEniJtWQc9j23i"}]}